Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms

International Journal of Stroke

Volumn 8, Issue 5, 2013, Pages 293-299

  Strbian, Daniel ^a   Piironen, Katja ^a   Meretoja, Atte ^a   Sairanen, Tiina ^a   Putaala, Jukka ^a   Tiainen, Marjaana ^a   Artto, Ville ^a   Rantanen, Kirsi ^a   Häppölä, Olli ^a   Kaste, Markku ^a   Lindsberg, Perttu J ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acute stroke therapy; Cerebral infarction; Ischemic stroke; rtPA; Thrombolysis; tPA

Indexed keywords

ALTEPLASE; HEPARIN;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84879465066     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00808.x     Document Type: Article

References (25)

1. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke 2002; 33 : 493-495.
2. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274 : 1017-1025.
3. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352 : 1245-1251.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 : 1581-1587.
5. Gray LJ, Ali M, Lyden PD, Bath PM. Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in acute stroke. J Stroke Cerebrovasc Dis 2009; 18 : 466-468.
6. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56 : 1015-1020.
7. Cocho D, Belvis R, Marti-Fabregas J etal. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005; 64 : 719-720.
8. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61 : 346-350.
9. Kleindorfer D, Kissela B, Schneider A etal. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35 : e27-29.
10. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. Ann Emerg Med 1999; 33 : 9-14.
11. Nedeltchev K, Schwegler B, Haefeli T etal. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007; 38 : 2531-2535.
12. Rajajee V, Kidwell C, Starkman S etal. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006; 67 : 980-984.
13. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005; 36 : 2497-2499.
14. Baumann CR, Baumgartner RW, Gandjour J, von Budingen H-C, Siegel AM, Georgiadis D. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006; 37 : 1332-1333.
15. Kohrmann M, Nowe T, Huttner HB etal. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis 2009; 27 : 160-166.
16. Meretoja A, Putaala J, Tatlisumak T etal. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41 : 1450-1458.
17. Lindsberg PJ, Soinne L, Tatlisumak T etal. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004; 292 : 1862-1866.
18. Khatri P, Kleindorfer DO, Yeatts SD etal. Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke 2010; 41 : 2581-2586.
19. Shrier DA, Tanaka H, Numaguchi Y, Konno S, Patel U, Shibata D. CT angiography in the evaluation of acute stroke. AJNR Am J Neuroradiol 1997; 18 : 1011-1020.
20. Tan JC, Dillon WP, Liu S, Adler F, Smith WS, Wintermark M. Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol 2007; 61 : 533-543.
21. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Experience. Ann Emerg Med 2005; 46 : 243-252.
22. Steffenhagen N, Hill MD, Poppe AY, Buchan AM, Coutts SB. Should you thrombolyse all or any stroke patients with baseline National Institutes of Health stroke scale scores ≤5? Cerebrovasc Dis 2009; 28 : 201-202.
23. Strbian D, Soinne L, Sairanen T etal. Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke 2010; 41 : 712-716.
24. Mishra NK, Lyden P, Grotta JC, Lees KR. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41 : 2612-2617.
25. Ingall TJ, O'Fallon WM, Asplund K etal. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35 : 2418-2424.